RESULTS

In vivo engineered CAR-T cell therapy: lessons built from COVID-19 mRNA vaccines (Int J Mol Sci, 2025)

In an academia-industry collaboration, Dr. Meng indicated the significance and implication of in vivo engineered CAR-T cell therapy. By bridging RNA-based technological insights, CAR-T therapy in vivo may evolve into a versatile and accessible treatment paradigm across diverse oncological landscapes.